-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $50

Benzinga·09/23/2026 15:07:05
Citigroup analyst Eric Joseph initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $50.